Insulin Market Report Highlights:

• The global insulin market size hit USD 28.33 billion in 2023.
• It is projected to reach USD 41.63 billion market size by 2033.
• It is set for a 4.2% annual climb till 2033.
• Analogs, lab-made versions, dominated the field in 2023 with a commanding 69.3% share.
• Asia Pacific took the biggest slice of the pie in 2023, gobbling up 42.6% of the insulin market.
• Rapid-acting insulin delivering a quick sugar blast will see the next decade’s fastest growth (5.5%).

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5101

Key Takeaways

• By region, Asia Pacific dominated the insulin market in 2023.
• By region, North America is estimated to grow with the fastest CAGR during the forecast period.

Segmentation A (Drug)

• By product, the premixed long-acting segment held the largest market share in 2023.
• By product, the rapid-acting segment is anticipated to grow at the fastest rate during the forecast period.
• By source, the insulin analog segment dominated the market in 2023.
• By distribution channel, the retail pharmacies segment dominated the market in 2023.
• By distribution channel, the hospital pharmacies segment is expected to grow at the fastest rate during the forecast period.
• By application, the type 2 diabetes segment dominated the market in 2023.
• By application, the gestational diabetes segment is expected to grow significantly during the forecast period.

Segmentation B (Delivery Device)

• By delivery device, the insulin pens segment held the largest market share in 2023.
• By delivery device, the insulin pumps segment is anticipated to grow at the fastest rate during the forecast period.
• By distribution channel, the retail pharmacies segment dominated the market in 2023.
• By distribution channel, the hospital pharmacies segment is expected to grow at the fastest rate during the forecast period.
• By application, the type 2 diabetes segment dominated the market in 2023.
• By application, the gestational diabetes segment is expected to grow significantly during the forecast period.

Industry at a Glance

The insulin market deals with the development, production, distribution, and innovation of insulin for chronic conditions of diabetes. One kind of hormone is insulin. The body uses insulin to facilitate the entry of blood glucose into cells, giving them the energy they need to operate. One of the main factors contributing to the development of diabetes is ineffective insulin. An estimated 530 million persons worldwide are projected to have diabetes, with a global incidence of 10.5% among adults between the ages of 20 and 79. Approximately 98% of diabetes diagnoses worldwide are for type 2 diabetes. However, this percentage varies greatly between nations.

According to data from the Diabetes Surveillance System, around 11.3 percent of adults (37.3 million) had diabetes in 2022; of them, 28.7 million had been diagnosed, 8.5 million were anticipated to remain undiagnosed, and 95% had type 2 diabetes. Insulin is the most effective therapy for diabetes, a difficult condition. In both outpatient and inpatient settings, the care of diabetes requires an interprofessional team approach at all times. The usage of insulin is rising due to the rising incidence of diabetes, which fuels the expansion of the insulin market.

Insulin Market Top Companies

• Eli Lilly
• Novo Nordisk
• Sanofi
• Boehringer Ingelheim
• Biocon
• Lupin Ltd.
• Wockhardt Ltd.
• Becton, Dickinson and Company
• B. Braun SE

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/global-insulin-market-size

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5101

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare